- Cybin (CYBN) has announced positive preclinical data from a study of its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004
- When inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including a longer duration of action, and improved bioavailability
- CEO Doug Drysdale sat down with Dave Jackson to discuss the news
- Inhaled CYB004 is being developed to overcome the limitations of IV DMT and become an important treatment option for anxiety disorders
- Cybin is a Canadian biopharmaceutical company
- Cybin Inc. (CYBN) opened trading at C$0.93 per share
Cybin (CYBN) has announced positive preclinical data from a pharmacokinetic study of its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004.
When inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including a longer duration of action, and improved bioavailability.
CEO Doug Drysdale sat down with Dave Jackson to discuss the news.
“In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability. CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic. As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians.”
Cybin is a Canadian biopharmaceutical company on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.
Cybin Inc. (CYBN) opened trading at C$0.93 per share.
